首页> 外国专利> ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES

机译:拮抗抗肿瘤坏死因子受体超家族多肽

摘要

Described are antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and/or myeloid-derived suppressor cells (MDSCs), to expand T effector cell populations or function, and to reduce the proliferation of, or directly kill, tumor cells, such as tumor cells that express TNFR2 antigen. The polypeptides, such as antibodies and antigen-binding fragments thereof, are TNFR2 antagonists, such as dominant TNFR2 antagonists. The polypeptides can be used to suppress the T-reg- or MDSC-mediated deactivation of tumor reactive T lymphocytes, expand populations of tumor-reactive cytotoxic T cells, and/or to directly kill TNFR2+ tumor cells. The antagonistic TNFR2 polypeptides described herein can be used to treat a wide variety of cancers and infectious diseases.
机译:描述是拮抗性TNFR2多肽,例如抗体和抗原结合片段,以及使用这些多肽抑制调节性T细胞(T-REGS)和/或髓样衍生抑制细胞(MDSC)的增殖,以扩大T. 效应细胞群或功能,并降低表达TNFR2抗原的肿瘤细胞等肿瘤细胞的增殖或直接杀死。 多肽,例如抗体和抗原结合片段,是TNFR2拮抗剂,例如显性TNFR2拮抗剂。 该多肽可用于抑制肿瘤反应性T淋巴细胞的T-Reg或Mdsc介导的失活,扩增肿瘤反应性细胞毒性T细胞的群体,和/或直接杀死TNFR2 +肿瘤细胞。 本文所述的拮抗性TNFR2多肽可用于治疗各种癌症和传染病。

著录项

  • 公开/公告号US2021340268A1

    专利类型

  • 公开/公告日2021-11-04

    原文格式PDF

  • 申请/专利权人 THE GENERAL HOSPITAL CORPORATION;

    申请/专利号US201917269315

  • 发明设计人 DENISE L. FAUSTMAN;

    申请日2019-08-20

  • 分类号C07K16/28;

  • 国家 US

  • 入库时间 2024-06-14 22:19:50

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号